OncoCyte Corporation (OCX)
NASDAQ: OCX
· Real-Time Price · USD
3.20
0.47 (17.22%)
At close: Jun 17, 2025, 3:59 PM
OncoCyte Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -6.67M | -33.51M | -13.49M | -4.53M | -9.13M | -15.99M | -6.49M | -8.33M | 3.03M | -44.98M | -9.33M | -8.3M | -10.29M | -35.88M | -13.8M | -10.49M | -3.92M |
Depreciation & Amortization | 491K | 563K | 340K | 326K | 335K | 325K | 426K | 457K | 472K | 1.28M | 1.37M | 1.36M | 1.22M | 1.08M | 1.2M | 1.47M | 453K |
Stock-Based Compensation | 473K | 549K | 354K | 202K | 464K | 611K | 608K | 834K | 834K | 2.62M | 3.18M | 2.23M | 2.01M | 1.71M | 1.85M | 2M | 1.29M |
Other Working Capital | n/a | 423K | -133K | -15K | -158K | -64K | 153K | -137K | 2.55M | 554K | -534K | -498K | -1.19M | 1.16M | -684K | 1.06M | -1.17M |
Other Non-Cash Items | n/a | 28.2M | 7.09M | -797K | 3.44M | 10.94M | 1.18M | 1.79M | -12.05M | 31.03M | -6.03M | -6.67M | -4.32M | 24.93M | 1.18M | 1.16M | 1.16M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | 65K | 1.9M | 24K | n/a | n/a | n/a | n/a | n/a | 97K | 138K | -1.79M | -7.56M |
Change in Working Capital | n/a | -1.16M | 160K | -1.18M | 1.02M | -510K | 113K | -1.61M | -1.97M | 407K | -539K | 82K | -1.89M | 1M | -1.52M | -424K | -1.26M |
Operating Cash Flow | -5.86M | -5.35M | -5.55M | -5.98M | -3.83M | -4.56M | -2.26M | -6.83M | -9.67M | -9.65M | -11.35M | -11.29M | -13.28M | -7.07M | -10.95M | -8.08M | -9.85M |
Capital Expenditures | n/a | -214K | 215K | -191K | -24K | -264K | -17K | n/a | n/a | -802K | -859K | -1.12M | -1.56M | -401K | -394K | -610K | -842K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | -354K | 231K | 123K | n/a | n/a | n/a | n/a | n/a | 11.11M | n/a | -4.28M | -7.43M |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | 367K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -307K | 4K | -302K | n/a | -24K | 138K | -1.51M | 123K | -1.37M | -4.34M | n/a | n/a | -1.56M | -11.11M | n/a | -10K | 10K |
Investing Cash Flow | -307K | -210K | -87K | -191K | -24K | 241K | -1.3M | 123K | -1.37M | -802K | -859K | -1.12M | -1.56M | -401K | -394K | -4.9M | -8.26M |
Debt Repayment | n/a | -82K | -86K | n/a | n/a | n/a | n/a | -29K | -28K | -100K | -528K | -416K | -385K | -282K | -418K | -418K | -416K |
Common Stock Repurchased | n/a | n/a | n/a | -5.39M | n/a | 1.12M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -202K | -37K | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 28.66M | -1.07M | -187K | 9.85M | n/a | -30K | -30K | -1.54M | n/a | n/a | n/a | 4.39M | 30K | 12K | 2.59M | 1M | -1.73M |
Financial Cash Flow | 28.56M | 10.84M | -255K | 9.85M | n/a | -30K | -30K | 12.27M | -28K | -100K | -528K | 36.79M | -355K | -269K | 8.21M | 547K | 69.87M |
Net Cash Flow | n/a | 5.27M | -5.89M | 3.68M | -3.85M | -4.35M | -3.58M | 5.57M | -9.7M | -10.55M | -12.78M | 24.42M | -15.19M | -7.74M | -3.13M | -12.44M | 51.76M |
Free Cash Flow | -5.86M | -5.57M | -5.34M | -6.17M | -3.85M | -4.83M | -2.28M | -6.83M | -9.67M | -10.45M | -12.21M | -12.41M | -14.84M | -7.47M | -11.34M | -8.69M | -10.69M |